DCOYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Decoy Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.17+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $622.40K
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.7%
0M of 1M shares
Institutional holders
4
2 new, 2 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
2 buys · 2 sales
Net bought $19.73K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| CVI Investments, Inc. | 708,565 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Steven Boyd | 65,503 | 9.99% | 13G (passive) | Jun 30, 2026 |
| Heights Capital Management, Inc. | 362,499 | 9.90% | 13G (passive) | Nov 11, 2025 |
| Elvin Lee | 204,270 | 6.09% | 13D (active) | Oct 27, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DCOY | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 4,034 | 0.62% | $29.00K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 256 | 0.04% | $1.84K | −765 | 0.00% |
| UBS Group AG | 25 | 0.00% | $180 | −521 | 0.00% |
| Caitong International Asset Management Co., Ltd | 2 | 0.00% | $14 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 4 | 0M | 0.7% | 2 / 0 | 2 / 2 | 0M | 0M |
| Q1 2026 | 4 | 0M | 0.2% | 4 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of DCOY | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 5,156 | 0.79% | $45.89K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 4,034 | 0.62% | $29.00K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 477 | 0.07% | $4.25K | 0.00% | May 31, 2026 |
| Horizon Kinetics Medical ETF | 21 | 0.00% | $149 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Frederick Pierce Ii | Chief Executive Officer | 34,844 | 5.32% | Sep 2, 2026 |
| Mark J. Rosenblum | Chief Financial Officer | 11,363 | 1.73% | Sep 2, 2026 |
| Peter Klaus Marschel | Chief Business Officer | 3,900 | 0.60% | Sep 2, 2026 |
| Barbara Louise Hibner | Chief Scientific Officer | 4,216 | 0.64% | Sep 2, 2026 |
| William K. McVicar | Director | 4,064 | 0.62% | Sep 2, 2026 |
| Patricia G. Gauthier | Director | 2,000 | 0.31% | Sep 2, 2026 |
| Jonathan I. Lieber | Director | 2,002 | 0.31% | Sep 2, 2026 |
| Arnold C. Hanish | Director | 8,418 | 1.28% | Sep 2, 2026 |
| Tess Burleson | Director | 2,002 | 0.31% | Sep 2, 2026 |
| Paul Lammers | Director | 2,001 | 0.31% | Sep 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jonathan I. Lieber Director | Aug 31, 2026 | Award | +2,000 | – | – | 2,002 |
| William K. McVicar Director | Aug 31, 2026 | Award | +3,000 | – | – | 3,002 |
| Arnold C. Hanish Director | Aug 31, 2026 | Award | +3,000 | – | – | 3,418 |
| Paul Lammers Director | Aug 31, 2026 | Award | +2,000 | – | – | 2,001 |
| Frederick Pierce Ii Chief Executive Officer | Aug 31, 2026 | Award | +33,455 | – | – | 34,844 |
| Patricia G. Gauthier Director | Aug 31, 2026 | Award | +2,000 | – | – | 2,000 |
| Barbara Louise Hibner Chief Scientific Officer | Aug 31, 2026 | Award | +4,216 | – | – | 4,216 |
| Peter Klaus Marschel Chief Business Officer | Aug 31, 2026 | Award | +3,900 | – | – | 3,900 |
| Tess Burleson Director | Aug 31, 2026 | Award | +2,000 | – | – | 2,002 |
| Mark J. Rosenblum Chief Financial Officer | Aug 31, 2026 | Award | +9,682 | – | – | 11,363 |
| Arnold C. Hanish Director | Dec 30, 2025 | Sale | −12 | $0.64 | $8 | 0 |
| Arnold C. Hanish Director | Dec 30, 2025 | Sale | −15 | $0.64 | $10 | 5,000 |
| Arnold C. Hanish Director | Nov 20, 2025 | Buy | +5,000 | $0.75 | $3.75K | 5,015 |
| Mark J. Rosenblum Exec VP Finance, CFO | Nov 20, 2025 | Buy | +20,000 | $0.80 | $16.00K | 20,177 |
| Mark J. Rosenblum Exec VP Finance, CFO | Feb 13, 2023 | Award | +6,432 | – | – | 21,851 |
| David J. Arthur Chief Executive Officer, Director | Feb 13, 2023 | Award | +14,300 | – | – | 48,019 |
| William K. McVicar Director | Jan 3, 2023 | Award | +1,440 | – | – | 1,788 |
| Jonathan I. Lieber Director | Jan 3, 2023 | Award | +1,440 | – | – | 2,940 |
| David J. Arthur Chief Executive Officer, Director | Jan 3, 2023 | Award | +20,000 | – | – | 33,719 |
| Paul Lammers Director | Jan 3, 2023 | Award | +1,440 | – | – | 1,718 |
| Tess Burleson Director | Jan 3, 2023 | Award | +1,440 | – | – | 2,722 |
| Mark J. Rosenblum Exec VP Finance, CFO | Jan 3, 2023 | Award | +8,000 | – | – | 15,419 |
| Bruce J. McCreedy Jr. Director | Jan 3, 2023 | Award | +1,440 | – | – | 1,788 |
| Arnold C. Hanish Director | Jan 3, 2023 | Award | +1,440 | – | – | 1,440 |
| Mark J. Rosenblum Exec VP Finance, CFO | Nov 3, 2022 | Award | +1,488 | $1.73 | $2.57K | 7,419 |
| David J. Arthur Chief Executive Officer, Director | Nov 3, 2022 | Award | +2,693 | $1.73 | $4.66K | 13,719 |
| Mark J. Rosenblum Exec VP Finance, CFO | Nov 3, 2022 | Award | +7,314 | $1.73 | $12.65K | 13,245 |
| David J. Arthur Chief Executive Officer, Director | Nov 3, 2022 | Award | +10,000 | $1.73 | $17.30K | 21,026 |
| David J. Arthur Chief Executive Officer, Director | Nov 3, 2022 | Award | +10,000 | $1.73 | $17.30K | 285,674 |
| Mark J. Rosenblum Exec VP Finance, CFO | Nov 3, 2022 | Award | +7,314 | $1.73 | $12.65K | 155,633 |
| Jonathan I. Lieber Director | Jun 7, 2022 | Buy | +37,500 | $0.19 | $7.13K | 37,500 |
| Tess Burleson Director | Jun 7, 2022 | Buy | +27,700 | $0.18 | $4.99K | 32,050 |
| William K. McVicar Director | Jun 6, 2022 | Buy | +26,553 | $0.19 | $5.05K | 26,553 |
| Arnold C. Hanish Director | Jun 3, 2022 | Buy | +28,000 | $0.18 | $5.04K | 46,350 |
| Mark J. Rosenblum Exec VP Finance, CFO | May 31, 2022 | Buy | +28,000 | $0.18 | $5.04K | 148,319 |
| David J. Arthur Chief Executive Officer, Director | May 26, 2022 | Buy | +708 | $0.18 | $127 | 282,382 |
| David J. Arthur Chief Executive Officer, Director | May 26, 2022 | Buy | +18,600 | $0.18 | $3.35K | 281,674 |
| David J. Arthur Chief Executive Officer, Director | May 26, 2022 | Buy | +3,400 | $0.18 | $612 | 263,074 |
| David J. Arthur Chief Executive Officer, Director | May 26, 2022 | Buy | +10,800 | $0.18 | $1.94K | 303,574 |
| David J. Arthur Chief Executive Officer, Director | May 26, 2022 | Buy | +10,392 | $0.18 | $1.87K | 292,774 |
| Mark J. Rosenblum Exec VP Finance, CFO | May 3, 2022 | Award | +10,000 | $0.19 | $1.90K | 120,319 |
| David J. Arthur Chief Executive Officer, Director | May 3, 2022 | Award | +10,000 | $0.19 | $1.90K | 259,674 |
| David J. Arthur Chief Executive Officer, Director | Mar 3, 2022 | Buy | +139,488 | $0.39 | $54.40K | 249,674 |
| Mark J. Rosenblum Exec VP Finance, CFO | Mar 3, 2022 | Buy | +76,246 | $0.39 | $29.74K | 110,319 |
| Mark J. Rosenblum Exec VP Finance, CFO | Nov 3, 2021 | Award | +7,787 | $0.72 | $5.61K | 34,073 |
| David J. Arthur Chief Executive Officer, Director | Nov 3, 2021 | Award | +7,939 | $0.72 | $5.72K | 110,186 |
| David J. Arthur Chief Executive Officer, Director | Aug 17, 2021 | Buy | +2,000 | $0.89 | $1.78K | 102,247 |
| David J. Arthur Chief Executive Officer, Director | Aug 17, 2021 | Buy | +2,000 | $0.90 | $1.80K | 100,247 |
| Arnold C. Hanish Director | Aug 10, 2021 | Buy | +7,000 | $0.88 | $6.16K | 18,350 |
| David J. Arthur Chief Executive Officer, Director | May 3, 2021 | Award | +9,822 | $0.57 | $5.60K | 96,247 |
| Mark J. Rosenblum Exec VP Finance, CFO | May 3, 2021 | Award | +9,563 | $0.57 | $5.45K | 26,286 |
| David J. Arthur Chief Executive Officer, Director | Nov 3, 2020 | Award | +4,879 | $0.56 | $2.73K | 86,425 |
| Mark J. Rosenblum Exec VP Finance, CFO | Nov 3, 2020 | Award | +4,723 | $0.56 | $2.64K | 16,723 |
| Arnold C. Hanish Director | Aug 21, 2020 | Buy | +4,000 | $0.98 | $3.92K | 11,350 |
| Arnold C. Hanish Director | Aug 21, 2020 | Buy | +4,000 | $0.98 | $3.92K | 11,350 |
| David J. Arthur Chief Executive Officer, Director | Aug 19, 2020 | Buy | +1,000 | $1.01 | $1.01K | 2,000 |
| David J. Arthur Chief Executive Officer, Director | Aug 19, 2020 | Buy | +1,000 | $1.01 | $1.01K | 1,000 |
| Mark J. Rosenblum Exec VP Finance, CFO | Aug 17, 2020 | Buy | +5,000 | $1.00 | $5.00K | 12,000 |
| Mark J. Rosenblum Exec VP Finance, CFO | Feb 19, 2020 | Buy | +2,000 | $0.95 | $1.90K | 7,000 |
| Scott Jordan Chief Business Officer | Feb 18, 2020 | Buy | +11,300 | $0.90 | $10.17K | 31,609 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.